CRNX - Crinetics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

3.438B

Cash

901M

Avg Qtr Burn

-44.61M

Short % of Float

9.61%

Insider Ownership

2.13%

Institutional Own.

-

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Paltusotine (SST2 agonist) Details Acromegaly	NDA Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Paltusotine (SST2 agonist) Details Neuroendocrine tumor, Carcinoid syndrome	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Atumelnant CRN04894 (ACTH antagonist) Details Congenital adrenal hyperplasia	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Atumelnant CRN04894 (ACTH antagonist) Details Cushing’s syndrome	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CRN04777 (SST5 agonist) Details Hyperinsulinism	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.